As a common disease in the poultry farming industry, avian influenza, especially the low pathogenic avian influenza (H9N2 subtype), has always been a key focus of breeding prevention and control due to its wide spread and high risks of secondary infections. MFIbio, deeply engaged in the field of animal disease prevention and control, combines industry needs with core technologies to provide scientific prevention and control solutions for global breeding practitioners, contributing to the healthy development of the industry.

The H9N2 subtype avian influenza virus belongs to the type A influenza virus of the Orthomyxoviridae family. The virus particles are spherical, with a diameter of 80-120 nanometers. Hemagglutinin (HA) and neuraminidase (NA) on the envelope are its key structures. Among the H9 subtype avian influenza prevalent globally, the H9N2 subtype is dominant. In China, the prevalent strains are mainly of the 9.4.2.5 clade or 9.2.4.6 clade, while in the Middle East and surrounding regions, the H9.4.1 clade is predominant.

Although the virus itself has weak pathogenicity, its greatest hazard lies in significantly reducing the resistance of poultry after infection, which easily leads to mixed infections with viruses such as Newcastle disease, infectious bronchitis, and bacteria. Eventually, this results in more than a 10% decrease in the hatching rate of poultry, along with symptoms such as bronchial obstruction, hemorrhage, pulmonary congestion, and consolidation, causing severe economic losses to the breeding industry.

Biosecurity is the foundation for preventing and controlling H9N2. Farms should establish strict isolation systems and physical barriers, thoroughly disinfect personnel, materials, and vehicles entering the farm area, and regularly carry out disinfection in the on-site environment to reduce the possibility of virus survival and spread.

Feeding and management are crucial for prevention and control. It is necessary to strictly control the temperature, humidity, and ventilation conditions in poultry houses to avoid infection induced by cold stress in poultry. Provide comprehensive and nutritious feed, and regularly add multi-vitamins, transfer factors, etc., to enhance the immune resistance of poultry.

Vaccine immunization is a core means of prevention and control. Due to significant differences in the prevalent H9N2 virus clades in different regions and low cross-protection, it is necessary to select vaccine products with strong targeting and advanced technology to achieve effective prevention and control.

Relying on a comprehensive microbial strain library, MFIbio has developed and produced the H9 series vaccines for the H9.4.1 clade prevalent in the Middle East and surrounding regions. Its core technical advantages provide a solid guarantee for the prevention and control effect.

The vaccine contains inactivated antigens of the H9N2 subtype 4.1.a and 4.1.b clades. The virus titer before inactivation is ≥ 3×10⁹.⁰EID₅₀/0.1mL, which accurately matches the prevalent virus strains in the target area and ensures the targeting of immunization.

A low-formaldehyde inactivation process is adopted, with a final formaldehyde concentration of only 0.8‰, which significantly reduces immune side effects. At the same time, through professional endotoxin treatment, the endotoxin content of the vaccine is ≤ 10EU/mL, minimizing the stress response of the toxin on poultry.

A composite oil adjuvant imported from France is selected. The vaccine has a viscosity of < 30cP, excellent fluidity, and no obvious stress on poultry during the peak egg-laying period after immunization, and can increase the antibody titer by at least 1 level. Combined with the low-temperature high-speed shear emulsification process, after pre-emulsification at 2000rpm, the vaccine is further sheared by a German high-speed emulsification equipment (9000rpm). The vaccine has uniform and fine particle size (average 1.13μm), good stability, and high absorption efficiency, ensuring stable disease resistance and production performance of poultry after immunization.

Thirty days after poultry immunization, there are no abnormalities in subcutaneous and muscular tissues. Its safety has been verified in practice and can be safely used in various poultry breeding scenarios.

The prevention and control of H9N2 subtype avian influenza requires a combination of "biosecurity + feeding management + precise immunization". With technological innovation and in-depth insight into prevalent virus strains, MFIbio's H9 series vaccines provide an efficient and safe prevention and control option for global poultry breeding, helping the industry reduce disease risks and achieve steady development.